BOCOM INTL: Raise target price for AKESO (09926) to HK$115, continues to be listed as a key recommended stock in the industry.

BOCOM INTL released a research report stating that the second phase III study of ivosidenib was successful, the first self-clearing product was approved, and the revenue forecast for AKESO (09926) for fiscal years 2025 to 2027 was raised by 0% to 6%. At the same time, the sales peak of "Ivosidenib" in mainland China and overseas market through PoS adjustment were adjusted to 6.1 billion RMB and 5.7 billion USD respectively. The target price of H shares was also raised to 115 Hong Kong dollars, with a "buy" rating, continuing to be listed as a key recommendation in the industry.